PGN-EDODM1 二期试验显示肌强直性 dystrophy 1 患者功能改善
Billy Joel Back on Stage; Alzheimer's and Sleep; Predicting Parkinson's Progression
药企 PepGen 报道,肌强直性 dystrophy 1 二期试验中,治疗药物 PGN-EDODM1 使患者功能指标有所改善。另有多项研究显示,慢波睡眠与阿尔茨海默病前期患者的认知轨迹相关,石油衍生润滑剂暴露与多发性硬化症风险增加有关。
— News and commentary from the world of neurology and neuroscience
by Judy George, Deputy Managing Editor, MedPage Today
November 10, 2026 • 2 min read
Musician and songwriter Billy Joel announced his first official show since his normal pressure hydrocephalus diagnosis. (People)
Topline results from a phase II study showed that treatment with investigational PGN-EDODM1 led to improvements in multiple functional measures in patients with myotonic dystrophy type 1, drugmaker PepGen said.
Patients diagnosed with iatrogenic cerebral amyloid angiopathy had a high rate of subsequent symptomatic intracerebral hemorrhage -- roughly a 20% yearly risk -- case series data showed. (Neurology)
Slow-wave sleep was linked to cognitive trajectories in preclinical Alzheimer's disease patients, with possibly stronger associations in men. (Alzheimer's Research & Therapy)
Final data from an open-label trial of the CD19-directed CAR T-cell therapy mivocabtagene autoleucel for stiff person syndrome -- first reported at this year's American Academy of Neurology (AAN) annual meeting -- were published in JAMA Neurology.
And JAMA Neurology published positive phase III trial data on azetukalner for focal seizures, which was also first reported at the AAN meeting.
In a correspondence to the New England Journal of Medicine, researchers demonstrated an initial proof of concept for chemogenetic neuromodulation in patients with drug-resistant epilepsy.
Older age, bilateral symmetric parkinsonism, and rapid eye movement sleep behavior disorder at diagnosis were associated with faster Parkinson's disease progression, an Italian cohort study showed. (Journal of Neurology, Neurosurgery & Psychiatry)
Exposure to petroleum-derived lubricants in the workplace was linked with a higher risk of multiple sclerosis in a Swedish population-based case-control study. (Neurology)
In a study of people treated for overactive bladder, beta-3 agonists were not associated with a lower dementia incidence compared with anticholinergics. (JAMA Network Open)
来源:MedPage Today · medpagetoday.com